Nonsteroidal anti-inflammatory drugs (NSAIDs) belong to a class of drugs used worldwide for the treatment of pain, fever and inflammatory diseases. Relatively new findings indicating that long-term use of NSAIDs is associated with lower risk of some types of cancer (1, 2) initiated a growing interest in this class of drugs. Numerous NSAID derivatives have been prepared in order to improve analgesic/anti-inflammatory activity, minimize side effects, prolong plasma half-life, increase COX1/COX2 selectivity, cytostatic activity and change water solubility or lipophilicity (3-5). However, our research is directed towards NSAID prodrugs and NSAID derivatives with dual cyclooxygenase/ 5-lipoxygenase inhibition or potential antioxidative and cytostatic activity. In this light, we have prepared and pharmacologically evaluated numerous amides (6, 7), phosphoramidate derivatives (8), semicarbazides and hydroxycarbamoylcarbazides (9), hydroxamic acid NSAID derivatives (10, 11) and polymer-NSAID conjugates (12, 13). Here, we describe syntheses of novel NSAID esters, derivatives of ibuprofen, ketoprofen and diclofenac, containing amino acid residue, urea and amide moieties, as potential NSAID prodrugs. A convenient synthetic method for the preparation of novel NSAID twin esters 6a-i containing amino acid residue, urea and amide moieties has been developed. The synthetic pathway applied for the preparation of target compounds and key intermediates 1-benzotriazolecarboxylic acid chloride (1), NSAID benzotriazolides 2a-c and N-(1-benzotriazolecarbonyl)-amino acids 3a-d involved benzotriazole as a synthetic auxiliary. The final preparation step of esters 6a-i included the solvent-free reaction of compounds 2a-c with amino acid derivatives 5a-g, bearing two hydroxyl groups, one at each terminal, beside urea and amide functionalities.
2-(4-Isobutyl-phenyl)-propionic acid 3-[2-(3-/3-[2-(4-isobutyl-phenyl)-propionyloxy]--propyl/-ureido-3-phenyl-propionylamino]-propyl ester (6b)
A mixture prepared from 0.307 g ibuprofen derivative (2a), 0.162 g L-phenylalanine 3-aminopropanol ureidoamide (5g) and TEA was heated at 100°C. Dichloromethane/ methanol 9.5:0.5 was used for column chromatography.
2-(3-Benzoyl-phenyl)-propionic acid 3-[2-(3-/3-[2-(3-benzoyl-phenyl)--propionyloxy]-propyl/-ureido)-propionylamino]-propyl ester (6c)
Ketoprofen derivative (2b, 0.355 g) in a mixture with L-alanine 3-aminopropanol ureidoamide (5a, 0.124 g) and TEA was heated at 125°C. Dichloromethane/methanol 9.5:0.5 was used for column chromatography.
2-(3-Benzoyl-phenyl)-propionic acid 3-[2-(3-/3-[2-(3-benzoyl-phenyl)-propionyloxy]--propyl/-ureido)-4-methyl-pentanoylamino]-propyl ester (6d)
Ketoprofen derivative (2b, 0.355 g) was mixed with L-leucine 3-aminopropanol ureidoamide (5b, 0.145 g) and TEA. The mixture was heated at 100°C. Cyclohexane/ethyl acetate 1:1 was used as eluent for column chromatography.
2-(3-Benzoyl-phenyl)-propionic acid 5-[2-(3-/5-[2-(3-benzoyl-phenyl)-propionyloxy]--pentyl/-ureido)-4-methyl-pentanoylamino]-pentyl ester (6e)
The titled compound was prepared from a mixture of 0.355 g ketoprofen derivative (2b), 0.173 g L-leucine 5-aminopenthanol ureidoamide (5c) and TEA heated at 100°C. Dichloromethane/methanol 9.5:0.5 was used for purification of the crude product by column chromatography.
2-(3-Benzoyl-phenyl)-propionic acid 2-[2-(3-/2-[2-(3-benzoyl-phenyl)-propionyloxy]--ethyl/-ureido)-2-phenyl-acetylamino]-ethyl ester (6f)
To synthesize the title compound, a mixture of 0.355 g ketoprofen derivative (2b), 0.141 g D-phenylglycine 2-aminoethanol ureidoamide (5d) and TEA was heated at 115°C
. Ethyl acetate/cyclohexane/methanol 3:1:0.1 was used as eluent for purification of the crude product by column chromatography.
2-(3-Benzoyl-phenyl)-propionic acid 2-[2-(3-/2-[2-(3-benzoyl-phenyl)-propionyloxy]--ethyl/-ureido)-3-phenyl-propionylamino]-ethyl ester (6g)
A mixture prepared from 0.355 g ketoprofen derivative (2b), 0.148 g L-phenylalanine 2-aminoethanol ureidoamide (5f) and TEA was heated at 100°C. Ethyl acetate/ cyclohexane/methanol 3:1:0.1 was used for column chromatography purification.
2-(3-Benzoyl-phenyl)-propionic acid 3-[2-(3-/3-[2-(3-benzoyl-phenyl)-propionyloxy]--propyl/-ureido)-phenyl-propionylamino]-propyl ester (6h)
Ketoprofen derivative (2b, 0.355 g) was mixed with 0.162 g L-phenylalanine 3-aminopropanol ureidoamide (5g) and TEA. The mixture was heated at 120°C. The crude product was purified on the chromatographic column using ethyl acetate/cyclohexane/ methanol 3:1:0.1 as eluent.
A mixture of 0.397 g diclofenac derivative (2c), 0.162 g L-phenylalanine 3-aminopropanol ureidoamide (5g) and TEA was heated at 100°C. Column chromatography with dichloromethane/methanol 9.5:0.5 as eluent was used for purification of the crude product. RESULTS AND DISCUSSION Synthesis of novel NSAID twin esters 6a-i containing amino acid residue, urea and amide moieties is described. The synthetic pathway applied for the preparation of target compounds is presented in Scheme 1. The key intermediates 1-benzotriazolecarboxylic acid chloride (1), NSAID benzotriazolides 2a-c, N-(1-benzotriazolecarbonyl) -amino acids 3a-d and ureidoamides 5a-g were prepared according to our procedures reported elsewhere (9, 12, 14, 15) . 1-Benzotriazolecarboxylic acid chloride (1) was synthesized from benzotriazole and triphosgene (14) and further used in the preparation of N-(1-benzotriazolecarbonyl)-amino acids 3a-d (15) . Two aliphatic (L-alanine, L-leucine) and two aromatic (D-phenylglycine, L-phenylalanine) amino acids were used in experiments. The prepared amino acid derivatives 3a-d were transformed to the corresponding chlorides 4a-d by means of thionyl chloride. In the reaction with aminoalcohols (2-aminoethanol, 3-aminopropanol or 5-aminopenthanol), they gave ureidoamides 5a-g (9) . 1-Benzotriazolecarboxylic acid chloride (1) was also used in the preparation of ibuprofen (2a), ketoprofen (2b) and diclofenac benzotriazolide (2c) (12) . The benzotriazole moiety in compounds 2a-c activated the nucleophilic substitution of molecules with hydroxyl groups present in ureido amides 5a-g, allowing preparation of the final esters 6a-i.
Structures of compounds 6a-i were deduced from analyses of their IR, 1 H and 13 C NMR spectra and were confirmed by elemental analysis (Table I) . Chemical shifts were consistent with the proposed structures of novel compounds. IR spectra of esters 6a-i showed characteristic bands for NH at 3302-3291 cm -1 and three different carbonyl groups at 1736-1718, 1663-1633 and 1570-1556 cm -1 , respectively. In 1 H NMR spectra, carbamide Table II .
CONCLUSIONS
The environmentally friendly solvent-free protocol for synthesis of novel NSAID esters containing amino acid residue, urea and amide moieties has been described. The prepared esters are potential NSAID prodrugs. Their analgesic, anti-inflammatory and antioxidative activities still remain to be evaluated.
